First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW

被引：0
|
作者：
Kang, Y-K. [1 ]
Shah, M. A. [2 ]
Shitara, K. [3 ]
Ajani, J. A. [4 ]
Lordick, F. [5 ]
Van Cutsem, E. [6 ]
Ilson, D. H. [7 ]
Klempner, S. J. [8 ]
Yamaguchi, K. [9 ]
Nakajima, T. [10 ]
Cao, Y. J. [11 ]
Li, R. [12 ]
Moran, D. [11 ]
Pophale, R. R. [13 ]
Ranganath, R. [13 ]
Xu, R-H. [14 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea
[2] Weill Cornell Med Coll, Med Oncol & Hematol Dept, New York, NY USA
[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA
[5] Univ Krebszentrum Leipzig, Univ Klinikum Leipzig, Med Dept, Leipzig, Germany
[6] UZ Leuven, Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium
[7] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA
[8] MGH Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA
[9] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan
[10] Astellas Pharma Global Dev, Med Dept, Northbrook, IL USA
[11] Astellas Pharma Global Dev Inc, Data Sci, Northbrook, IL USA
[12] Astellas Pharma Global Dev, Data Sci, Northbrook, IL USA
[13] Astellas Pharma Global Dev Inc, Med Affairs Dept, Northbrook, IL USA
[14] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1438P
引用
收藏
页码：S895 / S895
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
    Huang, Yufan
    You, Maojin
    Wu, Qundan
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
    Lordick, F.
    Van Cutsem, E.
    Shitara, K.
    Xu, R. -H.
    Ajani, J. A.
    Shah, M. A.
    Oh, M.
    Ganguli, A.
    Chang, L.
    Rhoten, S.
    Bhattacharya, P.
    Matsangou, M.
    Park, J. W.
    Pophale, R.
    Ranganath, R.
    Kang, Y. -K.
    ESMO OPEN, 2024, 9 (08)
  • [33] FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study.
    Jin, Zhaoyu
    Zhang, Yanqiao
    Liu, Funan
    Zhang, Shu
    Gong, Jifang
    Zhang, Miao
    Liang, Xinjun
    Wang, Junye
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
    Shah, Manish A.
    Shitara, Kohei
    Lonardi, Sara
    Chao, Yee
    Yamaguchi, Kensei
    Kukielka-Budny, Bozena
    Ryu, Min-Hee
    Ungureanu, Andrei
    Oh, Mok
    Chang, Lawrence
    Yang, Hongbo
    Chai, Xinglei
    Bhattacharya, Pranob P.
    Matsangou, Maria
    Ranganath, Radhika
    Ajani, Jaffer A.
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 325 - 325
  • [36] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-Hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Park, Jung Wook
    Oh, Mok
    Ajani, Jaffer A.
    LANCET, 2023, 401 (10389): : 1655 - 1668
  • [37] A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.
    Shen, Lin
    Peng, Zhi
    He, Ying
    Chen, Jing
    Hickingbottom, Barbara
    Lu, Jianfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 317 - 317
  • [38] First-line rilvegostomig (rilve) plus chemotherapy (CTx) in patients (pts) with HER2-negative (HER2-) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
    Herrero, F. Rivera
    Oh, D-Y.
    Shitara, K.
    Chen, J-S.
    Jiang, J.
    Liu, S.
    Dong, Z.
    Zhu, Q.
    Zhang, X.
    Umiker, B.
    Kumar, R.
    Rha, S. Y.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S887 - S887
  • [39] Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Schuler, M.
    Al-Batran, S-E.
    Zvirbule, Z.
    Manikhas, G.
    Lordick, F.
    Rusyn, A.
    Vinnyk, Y.
    Vynnychenko, I.
    Fadeeva, N.
    Nechaeva, M.
    Dudov, A.
    Gotovkin, E.
    Pecheniy, A.
    Bazin, I.
    Bondarenko, I.
    Melichar, B.
    Huber, C.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
12345